============================================================
QUALITATIVE ERROR ANALYSIS REPORT
Generated on: 2025-08-21 13:59:54
Model: Phi-3.5 2.7B
Dataset: HIV
============================================================

1. BASIC PERFORMANCE METRICS:
   Accuracy: 0.927
   Precision: 0.872
   Sensitivity: 1.000
   F1-Score: 0.932
   Total samples: 11302
   TP: 5651, TN: 4824, FP: 827, FN: 0

2. SMILES COMPLEXITY ANALYSIS:
   False Positives: 827 cases
     Avg combined SMILES length: 120.3 ± 98.6
   True Positives: 5651 cases
     Avg combined SMILES length: 131.8 ± 62.7
   True Negatives: 4824 cases
     Avg combined SMILES length: 112.4 ± 67.2

3. GENE TARGET COMPLEXITY ANALYSIS:
   False Positives: 827 cases
     Avg combined gene targets: 8.9 ± 17.0
   True Positives: 5651 cases
     Avg combined gene targets: 6.7 ± 9.4
   True Negatives: 4824 cases
     Avg combined gene targets: 4.9 ± 9.6

4. ORGANISM PATTERN ANALYSIS:
   Top false positives organism pairs:
     Humans - Humans: 586 cases
     Escherichia coli (strain K12) - Humans: 28 cases
     Humans - Escherichia coli (strain K12): 19 cases
     Humans - Mycobacterium tuberculosis: 7 cases
     Humans - Escherichia coli: 6 cases

5. MOST PROBLEMATIC DRUGS:
   Spaglumic acid: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Cemiplimab: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Sulfanilamide: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Eslicarbazepine acetate: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)
   Bacitracin: 1.000 error rate
     (3/3 errors: 3 FP, 0 FN)
   Diroximel fumarate: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)
   Icosapent: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Romiplostim: 1.000 error rate
     (2/2 errors: 2 FP, 0 FN)
   Azelastine: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)
   Myxothiazol: 1.000 error rate
     (1/1 errors: 1 FP, 0 FN)

6. SPECIFIC ERROR EXAMPLES:
   False Positives (predicted interaction, but no real interaction):
     1. Spaglumic acid + Regadenoson
        Organisms: Humans - Humans
        Gene targets: 1 - 1
     2. Tocilizumab + Tazobactam
        Organisms: Humans - Escherichia coli
        Gene targets: 1 - 2
     3. Afegostat + Cefuroxime
        Organisms: Mycobacterium tuberculosis - Clostridium perfringens (strain 13 / Type A)
        Gene targets: 3 - 1
     4. Rilmenidine + Cemiplimab
        Organisms: Humans - Humans
        Gene targets: 1 - 1
     5. Prednisolone acetate + (R)-Rolipram
        Organisms: Humans - Humans
        Gene targets: 1 - 2

7. SUMMARY INSIGHTS:
   - Model tends to over-predict interactions (more false positives than false negatives)
   - High sensitivity but lower precision - good at catching interactions but with some false alarms

Report generation completed successfully.
============================================================
